GLPwatch

Liraglutide Lowers Endothelial Vascular Cell Adhesion Molecule-1 in Murine Atherosclerosis Independent of Glucose Levels.

JACC Basic Transl Sci · 2022

Last updated 2026-09-01

In a study on mice with atherosclerosis, liraglutide reduced a marker of blood vessel inflammation called VCAM-1 by about threefold compared to untreated mice. The drug did not change cholesterol or blood sugar levels but lowered certain inflammatory signals in the body and reduced plaque buildup in the arteries.

AI summary of the abstract below.

JournalJACC Basic Transl Sci, 2022
Citations20
Relative citation ratio1.53
NIH percentile65
Molecules liraglutide

Abstract

The authors determined the effect of the GLP-1 receptor agonist liraglutide on endothelial surface expression of vascular cell adhesion molecule (VCAM)-1 in murine apolipoprotein E knockout atherosclerosis. Contrast-enhanced ultrasound molecular imaging using microbubbles targeted to VCAM-1 and control microbubbles showed a 3-fold increase in endothelial surface VCAM-1 signal in vehicle-treated animals, whereas in the liraglutide-treated animals the signal ratio remained around 1 throughout the study. Liraglutide had no influence on low-density lipoprotein cholesterol or glycated hemoglobin, but reduced TNF-α, IL-1β, MCP-1, and OPN. Aortic plaque lesion area and luminal VCAM-1 expression on immunohistology were reduced under liraglutide treatment.

Verbatim abstract via PubMed 36908664 ↗

Related research